The recent failure of several β-amyloid reducing therapies in late-stage clinical trial has led to increased interest in tau as a primary therapeutic target in AD and other dementias (Kang et al., 2011; Morris et al., 2011). The gene discussed is MAPT; the disease is Alzheimer disease.